Atopic and non-atopic effects of fish oil supplementation during pregnancy

被引：3

作者：

Bisgaard, Hans ^{[1
]}

Mikkelsen, Marianne ^{[1
]}

Rasmussen, Morten Arendt ^{[1
,2
]}

Sevelsted, Astrid ^{[1
]}

Schoos, Ann-Marie Malby ^{[1
,3
,4
]}

Brustad, Nicklas ^{[1
]}

Eliasen, Anders U. ^{[1
]}

Thorsen, Jonathan ^{[1
]}

Chawes, Bo ^{[1
,4
]}

Guerdeniz, Goezde ^{[1
]}

Morin, Andreanne ^{[5
]}

Stark, Ken ^{[6
]}

Stokholm, Jakob ^{[1
,3
]}

Ober, Carole ^{[5
]}

Pedersen, Casper Emil Tingskov ^{[1
]}

Bonnelykke, Klaus ^{[1
,4
]}

机构：

[1] Copenhagen Univ Hosp Herlev & Gentofte, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Gentofte, Denmark

[2] Univ Copenhagen, Fac Sci, Dept Food Sci, Copenhagen, Denmark

[3] Slagelse Sygehus, Dept Pediat, Slagelse, Denmark

[4] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark

[5] Univ Chicago, Dept Human Genet, Chicago, IL USA

[6] Univ Waterloo, Dept Kinesiol & Human Hlth, Waterloo, ON, Canada

来源：

THORAX | 2023年 / 78卷 / 12期

基金：

欧洲研究理事会;

关键词：

asthma; respiratory infection; BIRTH; CHILDREN; WHEEZE; ASTHMA; RISK;

D O I：

10.1136/thorax-2022-219725

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background We recently conducted a double-blinded randomised controlled trial showing that fish-oil supplementation during pregnancy reduced the risk of persistent wheeze or asthma in the child by 30%. Here, we explore the mechanisms of the intervention.Methods 736 pregnant women were given either placebo or n-3 long-chain polyunsaturated fatty acids (LCPUFAs) in the third trimester in a randomised controlled trial. Deep clinical follow-up of the 695 children in the trial was done at 12 visits until age 6 years, including assessment of genotype at the fatty acid desaturase (FADS) locus, plasma fatty acids, airway DNA methylation, gene expression, microbiome and metabolomics.Results Supplementation with n-3 LCPUFA reduced the overall risk of non-atopic asthma by 73% at age 6 (relative risk (RR) 0.27 (95% CI 0.06 to 0.85), p=0.042). In contrast, there was no overall effect on asthma with atopic traits (RR 1.42 (95% CI 0.63 to 3.38), p=0.40), but this was significantly modified by maternal FADS genotype and LCPUFA blood levels (interaction p<0.05), and supplementation did reduce the risk of atopic asthma in the subgroup of mothers with FADS risk variants and/or low blood levels of n-3 LCPUFA before the intervention (RR 0.31 (95% CI 0.11 to 0.75), p=0.016). Furthermore, n-3 LCPUFA significantly reduced the number of infections (croup, gastroenteritis, tonsillitis, otitis media and pneumonia) by 16% (incidence rate ratio 0.84 (95% CI 0.74 to 0.96), p=0.009).Conclusions n-3 LCPUFA supplementation in pregnancy showed protective effects on non-atopic asthma and infections. Protective effects on atopic asthma depended on maternal FADS genotype and n-3 LCPUFA levels. This indicates that the fatty acid pathway is involved in multiple mechanisms affecting the risk of asthma subtypes and infections.

引用

页码：1168 / 1174

页数：7